Form 4: Planet Labs CSO Sells Shares, Transfers to Trust

Planet Labs' Co-Founder and Chief Strategy Officer, Robert H. Schingler, reported a sale of Class A Common Stock and a transfer of shares to a revocable trust.

Summary

• Robert H. Schingler, Co-Founder and Chief Strategy Officer of Planet Labs PBC, reported transactions involving Class A Common Stock.
• On December 26, 2025, Schingler sold 73,782 shares of Class A Common Stock at a weighted average price of $19.3548 per share.
• This sale was executed under a Rule 10b5-1 trading plan adopted on July 14, 2025.
• On December 29, 2025, Schingler transferred 330,171 shares of Class A Common Stock to the Ulysses Trust 02021.1, a revocable trust where he and his spouse serve as trustees.
• Following these transactions, Schingler directly beneficially owns 834,558 shares, which includes 834,558 Restricted Stock Units (RSUs) vesting quarterly.
• The Ulysses Trust 02021.1 indirectly beneficially owns 330,171 shares.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions, including a pre-planned sale and a trust transfer, which are common and do not inherently indicate positive or negative company performance.

Positives

• The sale of 73,782 shares was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than an immediate reaction to market conditions.

Negatives

• An insider sale of 73,782 shares, even if pre-planned, reduces direct ownership and could be perceived negatively by some investors.

Risks

• Potential negative market perception from an insider sale, even if executed under a pre-planned Rule 10b5-1 trading plan.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on insider transactions.

Industry Context

This Form 4 filing details an insider transaction and does not provide information directly related to broader industry trends or competitive landscape for Planet Labs PBC. Insider sales, even pre-planned, are common in the technology sector as executives manage personal finances and diversify portfolios.

Comparison to Industry Standards

• This filing is a standard insider transaction report (Form 4) and does not contain information that allows for a direct comparison of company results to global benchmarks or specific comparable companies/projects.
• Insider trading activity is a common occurrence across all publicly traded companies, and the use of a 10b5-1 plan is a standard practice for executives to manage stock sales in a compliant manner.

Related Party Transactions

• Transfer of 330,171 shares to Ulysses Trust 02021.1, a revocable trust where the reporting person and his spouse serve as trustees, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May observe a reduction in direct insider ownership, though mitigated by the 10b5-1 plan. The transfer to a trust maintains beneficial ownership within the family.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Continued vesting of 834,558 RSUs in equal quarterly installments on the 15th of March, June, September, and December.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, including a pre-planned sale under a Rule 10b5-1 plan and a transfer to a family trust. Such transactions are common for executives managing personal finances and do not typically signal a change in the company's fundamental outlook or operational performance. While an insider sale reduces direct ownership, the pre-planned nature and the transfer to a trust suggest personal financial planning rather than a lack of confidence in the company. Therefore, the filing itself does not provide sufficient new information to warrant a change from a 'hold' position, assuming the investor's existing thesis on Planet Labs remains intact.

Keywords

Planet Labs, PL, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Robert H. Schingler, Chief Strategy Officer, Director, Trust Transfer, Equity Transaction